CSL to acquire Chinese blood plasma fractionator

The Australian blood plasma company buys a majority stake in a Chinese firm for $352 million in hopes of broadening its offering in China. It's the first such deal by a foreign firm.

CSL to acquire Chinese blood plasma fractionator

Australian blood plasma giant CSL is to strengthen its footprint in China with a $352 million deal for an 80 per cent stake in a Chinese plasma factionator.

CSL will acquire the stake in Wuhan Zhong Yuan Rui De Biological Products Ruide from Humanwell Healthcare Group, a Shanghai-listed pharmaceutical company, CSL said in a statement on Tuesday. The deal is subject to regulatory approval.

The deal the first foreign purchase...

To continue reading, please login or register for free

Click for more on: china | health | acquisitions | csl | ruide | australia

Print Edition

FinanceAsia Print Edition

CONFERENCES